Respiratory Infections

More than 13 million children did not receive their first DTP vaccine dose in 2019—and investigators anticipate the 2020 rate will be worse.

Phase 2 data hints the immune response-modulating therapy could play a role in burdened hospital settings.

Findings from Michigan show financial, mental health, and cardiopulmonary impacts are prevalent in patients 2 months after hospital care.

The World Health Organization released a brief addressing medical concerns as the influenza season begins in the northern hemisphere during the COVID-19 pandemic.

The new research letter also highlights a concerning rate of infection among Latino patients.

A new survey shows just 2% of children with rheumatic disease reported COVID-19 positive test results or symptoms through early May.

New findings show subsequent drops in incidence, hospitalizations, and mortalities once the state set stay-at-home orders, mask mandates, and contact tracing.

The test simultaneously recognizes the S1 and S2 subunits of the virus' spike protein in one sample, providing better sensitivity.

Data suggest New York City COVID-19 cases could have been reduced by 80% in two months if social distancing was implemented a week earlier than it was.

A Medicare program provided more point-of-care testing devices this summer. Yet, even hot-spot facilities are far more likely to receive results in ≥3 days than 1.

New data may evidence oral care as a therapeutic measure to reduce bacterial and viral spread.

The hospital found just 2 cases in their first 12 weeks were borne in the facility. A study author provides insight.

An investigator shares detail into how the neutralizing, immune-signaling molecule may provide continued success against the virus.

Ravina Kullar, PharmD, MPH, reflects on rapid advances in COVID-19 treatment understanding during IDWeek 2020.

The study population comprised 224 patients admitted to the ICU with influenza, and the overall rate of IPA was 3.1% (7/224).

New data highlight the need for more antimicrobial stewardship adoption in emergency care settings.

In an effort to expand serotype coverage beyond 13, a 20-valent pneumococcal conjugate vaccine, PCV20, is currently in development.

New data presented at IDWeek showed more than half observed households with a COVID-19 case reported a secondary infection, oftentimes within 3 days.

Phase 1 data and a history of benefit for worsening respiratory infections show promise for the therapy.

In a phase 1/2 randomized clinical trial, GlaxoSmithKline’s RSVPreF3 vaccine elicits a response.

Cefiderocol was noninferior to high-dose, extended-infusion meropenem in terms of all-case mortality in patients with gram-negative nosocomial pneumonia and showed similar clinical and microbiological efficacy to best available therapies in carbapenem-resistant, gram-negative bacterial infections, according to 2 recently released studies.

A summary of new studies surrounding COVID-19 comorbid effects.

After a series of positive developments, the antiviral agent joins a quartet of candidates that failed to improve severely ill COVID-19 status in the Solidarity study.

A recently proposed effort toward herd immunity through younger person COVID-19 infection was met with contention from public health leaders and experts.

A 25-year-old male in Nevada was hospitalized due to a different SARS-CoV-2 strain 2 months after recovering from a first case.

Fundamental aspects of immunity to SARS-CoV-2 remain elusive. Here is an examination of some potential clues to protection.

A collection of expert perspectives on what the virus itself may mean for future crises.

New ACTT-2 data shows a marked benefit from the combination regimen versus lone remdesivir.

ACTT-1 findings for the Gilead antiviral show it improved chance of clinical improvement by 50% in very ill COVID-19 patients.